Thyroid Journal

ATA's official monthly journal, is peer-reviewed for topics ranging from the molecular biology of the thyroid gland to clinical management of thyroid disorders.

[Thyroid Journal @thyroidjournal]

@SageJournals, in partnership with the @AmThyroidAssn, is pleased to announce the publication of the 2026 ATA Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum in the #ThyroidJournal
https://t.co/gIPZroP64Y
#medtwitter #endotwitter

[Thyroid Journal @thyroidjournal]

Check out the @AmThyroidAssn new Multidisciplinary Consensus Statement on Ambulatory Thyroid Surgery, which outlines key strategies to ensure patient safety and optimal outcomes.
Read More: https://t.co/LWSOMkeiiY
#ThyroidJournal #medtwitter #endotwitter

[Thyroid Journal @thyroidjournal]

What links BRAFV600E and TERT in aggressive thyroid cancer? A team from @UofT identified DDX21 as a key mediator—driven by MAPK signaling-which partners with TERT to boost rRNA transcription and tumor growth, pointing to a new therapeutic target.
https://t.co/KGz9AO5DrU

[Thyroid Journal @thyroidjournal]

Does active surveillance affect quality of life vs immediate surgery in low-risk PTC? A new @ThyroidJournal study from the Canadian Active Surveillance Study Group found similar QoL and anxiety at ~3 years https://t.co/vc2aDD8SaL
@AmThyroidAssn #ThyroidJournal #medtwitter

[Thyroid Journal @thyroidjournal]

How does long-term iodine excess affect TSH? Does reducing iodine excess normalize TSH over time? A 20-year study suggests not—prior excess is linked to higher TSH/hypothyroidism, w/aging and iodine history interacting to shape long-term thyroid function.
https://t.co/u83ak6Pqhi

[Thyroid Journal @thyroidjournal]

Can 3D tools improve margin assessment in invasive thyroid cancer surgery? A team @IcahnMountSinai introduces MarginView3D, enabling real-time surgeon–pathologist collaboration—helping achieve precise resections in advanced disease.
https://t.co/aOVU31zxbB
@AmThyroidAssn

[Thyroid Journal @thyroidjournal]

Do patient perceptions influence the radioiodine experience? A new @ThyroidJournal study shows many patients forget key precautions yet add their own, reporting multiple side effects—suggesting beliefs strongly shape adherence and symptom burden.
https://t.co/PYibmAHzcg

[Thyroid Journal @thyroidjournal]

Is active surveillance safe for recurrent thyroid cancer? A meta-analysis found ~23% progression, possibly underestimated to 35–70% due to follow-up loss - suggesting caution for AS, especially in patients with higher Tg or advanced stage. https://t.co/njQMYVEaqR
@AmThyroidAssn

[Thyroid Journal @thyroidjournal]

Do all RAS-positive thyroid nodules need surgery? A @UCalgary study found many are benign or low risk, with low growth rates on follow-up—supporting active surveillance as a safe alternative in selected patients. https://t.co/6PT5gborsY
@AmThyroidAssn #ThyroidJournal

[Thyroid Journal @thyroidjournal]

Why do thyroid US risk stratification systems (RSS) perform differently? A study from Korea comparing 5 different RSSs found major variation in sensitivity/biopsy rates driven by differing criteria—highlighting need for a unified TIRADS system.
https://t.co/jxWBrmN1mf

[Thyroid Journal @thyroidjournal]

Why is TPO expression reduced in thyroid cancer? A new @ThyroidJournal study shows DNA hypermethylation silences TPO via MBD2 recruitment;TPO methylation assays may accurately distinguish malignant from benign nodules-offering a promising diagnostic tool
https://t.co/cwL1Wnod1j

[Thyroid Journal @thyroidjournal]

Can rehab exercises help swallowing after thyroidectomy? A @ThyroidJournal RCT shows a 3-month program of neck, swallowing & voice exercises improved swallowing-related QoL at 1 and 6 months vs usual care—safe, with only mild early pain increase.
https://t.co/cxT2Edk71J

[Thyroid Journal @thyroidjournal]

What is the long-term thyroid impact of Rx for children with high-risk neuroblastoma? A new study found >50% of survivors developed thyroid toxicity-esp after molecular radiotherapy, immunotherapy, or busulfan, underscoring need for lifelong follow-up.
https://t.co/waM3KSiTRn

[Thyroid Journal @thyroidjournal]

Does levothyroxine treatment raise cardiovascular risk in women with hypothyroidism? In the SWAN cohort, @mettleson and coauthors report no increased risk of MI, stroke, HF, or revascularization in LT4-treated women vs those without thyroid disease. https://t.co/ctnmULX8kj

[Thyroid Journal @thyroidjournal]

NEW pilot-grant program! 🔬 ATA is funding 15 early-career investigators with up to $10K for innovative thyroid research. Applications due May 15. Associate & Early Career Members—this is your opportunity! Apply: https://t.co/6BWjoSdfiF
#ThyroidResearch #ResearchGrant #ATA

[Thyroid Journal @thyroidjournal]

How can we measure quality of life in thyroid cancer survivors? A new @ThyroidJournal study introduces the TCQOLI—a validated, thyroid-cancer–specific utility index designed for QALY estimates, cost-effectiveness analyses, and patient-centered decisions. https://t.co/CGtPWjYHAr

[Thyroid Journal @thyroidjournal]

Does levothyroxine benefit older adults with subclinical hypothyroidism? In the Emulated Target Trial of >22,000 UK patients, authors from @sunderlanduni report lower CV events & all-cause mortality with LT4—esp. when TSH exceeded age-specific ranges. https://t.co/2XChkQdeQ0

[Thyroid Journal @thyroidjournal]

What are risks of permanent hypoparathyroidism after thyroidectomy? Recent study from Korea found higher rates of kidney stones, renal insufficiency & major cardiac events in patients with PO-hypoPT—highlighting need for ongoing renal & CV monitoring. https://t.co/HfFcwnAxYz

[Thyroid Journal @thyroidjournal]

Can neonatal fragment crystallizable receptor (FcRn) blockers assist in treatment of refractory Graves’ disease? New @ThyroidJournal case report describes rapid normalization of thyroid hormones wi/batoclimab & sustained euthyroidism after stopping therapy https://t.co/fibvyExSga

[Thyroid Journal @thyroidjournal]

New options for BRAFV600E-negative anaplastic thyroid cancer? In a phase 2 @ThyroidJournal trial, anlotinib + sintilimab achieved a 48% response rate & median PFS ~9.6 months, with manageable toxicity—supporting further study. https://t.co/HYp6jep4BI
#ThyroidJournal #medtwitter